0001979693-26-000007.txt : 20260204
0001979693-26-000007.hdr.sgml : 20260204
20260204184112
ACCESSION NUMBER: 0001979693-26-000007
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20260204
DATE AS OF CHANGE: 20260204
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 26599767
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: McAuliffe Sean
CENTRAL INDEX KEY: 0001979693
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O TAYSHA GENE THERAPIES, INC.
STREET 2: 3000 PEGASUS PARK DRIVE, SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
144
1
primary_doc.xml
144
0001979693
XXXXXXXX
LIVE
0001806310
TAYSHA GENE THERAPIES, INC.
001-39536
3000 PEGASUS PARK DRIVE
SUITE 1430
DALLAS
TX
75247
214-612-0000
Sean McAuliffe
Affiliate - Chief Business Officer
Common Stock
Maxim Group LLC
300 Park Avenue, 16th Floor
New York
NY
10022
914
4314.08
273919373
02/04/2026
Nasdaq
Common Stock
02/03/2026
RSU Award
Issuer
N
914
02/03/2026
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
N
Sean McAuliffe
c/o Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Suite 1430
Dallas
TX
75247
Common Stock
01/23/2026
36071
171337.25
Sean McAuliffe
c/o Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Suite 1430
Dallas
TX
75247
Common Stock
01/26/2026
10894
50221.34
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
02/04/2026
/s/ Sean McAuliffe